Corcept Therapeutics (CORT) shares have dropped again after reports emerged that the FDA issued multiple warnings advising the company against submitting its drug application for relacorilant. The stock decline follows earlier losses linked to concerns over the company’s financial disclosures.
Hagens Berman, a law firm representing investors affected by the stock’s fall, is encouraging those who experienced losses to reach out for potential legal action.
**Why this matters**
The FDA’s warnings on relacorilant’s application could delay or impact the approval process, affecting Corcept Therapeutics’ future prospects. Investor confidence has been shaken by these developments alongside prior allegations of misleading financial statements, contributing to volatility in the company’s stock price.